查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088668

持續皮下胰島素輸注市場：按產品類型、胰島素類型、技術類型、年齡層和最終用戶分類－2026-2032年全球市場預測

Continuous Subcutaneous Insulin Infusion Market by Product Type, Insulin Type, Technology Type, Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，緩釋皮下胰島素輸注市場將成長至 16.403 億美元，複合年成長率為 10.42%。

主要市場統計數據
基準年 2025 8.1936億美元
預計年份：2026年 9.0162億美元
預測年份 2032 16.403億美元
複合年成長率 (%) 10.42%

持續皮下胰島素輸注（CSII），俗稱胰島素幫浦療法，正從一種特殊的糖尿病治療方法轉變為技術驅動型糖尿病管理的核心支柱。 CSII 透過可程式設計的基礎胰島素和大劑量投藥劑量輸送速效胰島素，幫助第 1 型糖尿病患者以及某些需要胰島素治療的 2 型糖尿病患者比傳統注射方案更精準地控制血糖值波動。

市場成長動能主要受以下因素驅動：全球糖尿病負擔日益加重、持續血糖監測（CGM）的廣泛應用以及臨床對自動化胰島素輸注系統的需求。世界衛生組織（WHO）的數據顯示，糖尿病患者人數從1990年的2億增至2022年的8.3億，凸顯了對擴充性、循證的胰島素輸註解決方案的長期需求。臨床指引日益認可胰島素幫浦與CGM結合的綜合治療方案，認為其是提高血糖達標時間、降低低血糖風險以及支持個人化糖尿病治療的關鍵選擇。

持續性皮下胰島素輸注（CSII）和自動化胰島素給藥的變革性變化

胰島素幫浦、動態血糖監測感測器、行動應用程式和演算法驅動的管理支援的融合正在重塑持續皮下胰島素輸注（CSII）的格局。雖然需要高度客製化編程的患者仍在使用管式胰島素泵，但貼片式胰島素泵憑藉其隱藏的佩戴方式和簡化的用戶體驗正日益受到青睞。互通的胰島素幫浦平台也正在改變採購決策，使相容的組件能夠在更廣泛的數位化糖尿病生態系統中運作。

人工智慧對胰島素幫浦治療的累積影響

人工智慧 (AI) 透過改善血糖值預測、模式識別、遠端監測和臨床決策支持，為持續皮下胰島素輸注 (CSII) 帶來累積價值。 AI 驅動的分析可以識別復發性高血糖、夜間低血糖、大劑量投藥洩漏和胰島素敏感性變化等風險，幫助臨床醫生更有效率地個性化胰島素幫浦設置，並在患者門診就診期間提供支持。

關於CSII實施的關鍵區域見解

北美地區憑藉其成熟的內分泌醫療網路、完善的醫保報銷機制、高普及率的持續血糖監測儀（CGM）以及較早獲批的自動胰島素輸注系統，仍然是持續皮下胰島素輸注（CSII）應用的領先地區。尤其值得一提的是，美國擁有舉足輕重的地位，已通過核准的胰島素幫浦、CGM和互操作系統往往成為全球商業化和臨床證據標準的標竿。同時，加拿大的省級醫保報銷模式使得胰島素幫浦治療的可近性較為系統化，但具體情況仍有差異。

針對CSII相關人員的關鍵群體特定見解

七國集團（G7）憑藉先進的醫保報銷機制、完善的糖尿病技術推廣路徑、積極的臨床試驗活動以及對整合了持續血糖監測（CGM）的胰島素泵療法的早期應用，成為全球持續皮下胰島素輸注（CSII）創新發展的基石。歐盟正透過《醫療設備法規》（MDR）框架下統一的醫療設備法規來擴大其市場規模，但成員國的醫保報銷決策仍對病患的就醫途徑、採購速度和臨床應用產生重大影響。

對CSII市場主要國家的洞察

美國是CSII市場最具影響力的國家，這得益於其先進的胰島素幫浦產品組合、與CGM的整合、基於遠端醫療的內分泌學、完善的醫療設備認證流程以及強大的患者權益倡導。加拿大緊隨其後，但各省的保險報銷政策存在差異。同時，儘管公共醫療資源有限且專科醫生數量不均，墨西哥和巴西的民營市場需求仍在增加。在英國、德國、法國、義大利和西班牙，基於指引的糖尿病照護、醫療技術評估和保險報銷評估備受重視，但就診速度因保險公司、地區和臨床合格標準而異。俄羅斯由於採購流程複雜、保險報銷限制以及技術供應的挑戰，面臨更嚴格的市場環境。

為行業領導者提供的實用建議

產業領導者應優先考慮互通性、以患者為中心的持續皮下胰島素輸注（CSII）平台，這些平台應整合輸注幫浦、持續血糖監測儀（CGM）、劑量演算法、行動連線和安全的雲端分析功能。透過降低訓練負擔、提高輸注裝置可靠性、延長臨床檢驗範圍內的佩戴時間、簡化部署流程以及展示可衡量的結果（例如增加目標範圍內的血糖維持時間、減少嚴重低血糖發生率和減輕糖尿病管理負擔），企業將獲得競爭優勢。

調查方法

本次高階主管評估採用基於三角測量的研究方法，結合了檢驗的二級資訊來源、監管資料庫、同行評審的臨床文獻、公共衛生資料集、報銷政策、產品標籤、醫療設備核准記錄和糖尿病護理調查方法。評估內容包括資訊來源的可靠性、時效性、地理相關性、方法透明度以及與既定臨床和監管證據的一致性。

結論

持續皮下胰島素輸注（CSII）正進入一個以自動化、互通性、人工智慧驅動的個人化以及基於療效的治療方案為特徵的新階段。隨著全球糖尿病盛行率的持續上升，胰島素幫浦治療有望在改善血糖控制、減輕患者負擔以及支持數據驅動的臨床護理方面發揮更大的作用，尤其適用於需要特定胰島素的第1型糖尿病和第2型糖尿病患者。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：持續皮下胰島素輸注市場：依產品類型分類

  • 胰島素幫浦
    • 有線泵
    • 貼片幫浦
  • 水泵配件
    • 注射套裝
    • 電池
    • 水庫
    • 修補
  • CSII 軟體與數位平台
    • 遠端監控應用程式
    • 數據管理和分析平台
    • 自動胰島素注射

第8章：持續皮下胰島素輸注市場：依胰島素類型分類

  • 快速起效的類似物
  • 標準胰島素
  • 短期型

第9章：持續皮下胰島素輸注市場：依技術類型分類

  • 傳統胰島素泵
  • 配備感測器的泵
  • 先進的封閉回路型系統

第10章：持續皮下胰島素輸注市場：依年齡層別分類

  • 成人
  • 老年人
  • 兒童

第11章：持續皮下胰島素輸注市場：依最終用戶分類

  • 門診治療
  • 居家照護
  • 醫院
  • 糖尿病診所

第12章：持續皮下胰島素輸注市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：持續皮下胰島素輸注市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：持續皮下胰島素輸注市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • B. Braun SE
  • Baxter International, Inc.
  • Becton, Dickinson and Company
  • Bigfoot Biomedical, Inc.
  • BPL Medical Technologies Private Limited
  • CeQur SA
  • F. Hoffmann-La Roche Ltd.
  • Forbion
  • Fresenius SE & Co. KGaA
  • Insulet Corporation
  • MannKind Corporation
  • Medtronic PLC
  • MicroPort Scientific Corporation
  • Nipro Corporation
  • Pharmasense AG
  • Sanofi SA
  • Shinmyung Mediyes CO., LTD.
  • SOOIL Developments Co., Ltd.
  • Tandem Diabetes Care, Inc.
  • Terumo Group
  • Ypsomed AG
Product Code: MRR-A339DAEFA756

The Continuous Subcutaneous Insulin Infusion Market is projected to grow by USD 1,640.30 million at a CAGR of 10.42% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 819.36 million
Estimated Year [2026] USD 901.62 million
Forecast Year [2032] USD 1,640.30 million
CAGR (%) 10.42%

Continuous Subcutaneous Insulin Infusion (CSII), commonly known as insulin pump therapy, is moving from a specialist diabetes intervention to a core pillar of technology-enabled diabetes management. CSII delivers rapid-acting insulin through programmable basal rates and bolus dosing, helping people with type 1 diabetes and selected insulin-requiring type 2 diabetes populations manage glycemic variability with greater precision than conventional injection schedules.

Market momentum is supported by the rising global diabetes burden, broader use of continuous glucose monitoring (CGM), and clinical demand for automated insulin delivery systems. The World Health Organization reports that the number of people living with diabetes increased from 200 million in 1990 to 830 million in 2022, underscoring the long-term need for scalable, evidence-based insulin delivery solutions. Clinical guidelines increasingly recognize insulin pump therapy and CGM-integrated care as important options for improving time-in-range, reducing hypoglycemia risk, and supporting individualized diabetes treatment.

Transformative Shifts in CSII and Automated Insulin Delivery

The CSII landscape is being reshaped by the convergence of insulin pumps, CGM sensors, mobile applications, and algorithm-driven dosing support. Tubed pumps continue to serve patients needing highly customizable programming, while patch pumps are expanding appeal through discreet wearability and simplified user experience. Interoperable pump platforms are also changing procurement decisions by allowing compatible components to work within broader digital diabetes ecosystems.

Regulatory pathways and payer expectations are shifting toward demonstrable outcomes, usability, cybersecurity, and real-world evidence. Hybrid closed-loop systems, first cleared in the United States in 2016, accelerated the transition from manual pump therapy to automated insulin delivery, making time-in-range, hypoglycemia reduction, infusion set performance, device reliability, and patient-reported burden key competitive indicators.

Cumulative Impact of AI on Insulin Pump Therapy

Artificial intelligence is adding cumulative value across CSII by improving glucose forecasting, pattern recognition, remote monitoring, and clinical decision support. AI-enabled analytics can identify recurring hyperglycemia, nocturnal hypoglycemia risk, missed boluses, and insulin sensitivity changes, helping clinicians personalize pump settings more efficiently while supporting patients between clinic visits.

The most defensible AI opportunity is not fully autonomous care, but safer, explainable augmentation of insulin therapy. Industry leaders must align AI models with regulatory expectations for software as a medical device, protect sensitive health data, validate performance across diverse populations, and maintain transparent human oversight in dosing-related recommendations. As automated insulin delivery expands, AI will be most valuable when it strengthens safety, usability, adherence, and clinically validated personalization rather than replacing clinician judgment.

Key Regional Insights Across CSII Adoption

North America remains a leading CSII adoption region due to mature endocrinology networks, established reimbursement pathways, high CGM penetration, and early regulatory acceptance of automated insulin delivery. The United States is particularly influential because cleared pumps, CGMs, and interoperable systems often set reference points for global commercialization and clinical evidence expectations, while Canada's provincial reimbursement models create structured but variable access to insulin pump therapy.

Europe benefits from strong diabetes care infrastructure, national health systems, and procurement models that increasingly evaluate quality-adjusted outcomes, device usability, safety, and long-term clinical value. Asia-Pacific is expanding as China, Japan, India, South Korea, and Australia improve diabetes technology access, although affordability, specialist availability, diabetes education, and reimbursement depth remain uneven. Latin America shows demand growth in urban private healthcare systems, especially where specialist diabetes care and CGM use are increasing, while public-sector access remains constrained. The Middle East is supported by high diabetes prevalence, premium hospital investment, and national noncommunicable disease strategies, particularly in higher-income Gulf countries. Africa remains earlier stage, with CSII access shaped by insulin affordability, supply continuity, limited reimbursement for advanced diabetes devices, and uneven availability of trained endocrinology teams.

Key Group Insights for CSII Stakeholders

G7 markets anchor global CSII innovation through advanced reimbursement systems, established diabetes technology pathways, clinical trial activity, and early adoption of CGM-integrated pump therapy. The European Union adds scale through harmonized medical device regulation under the Medical Device Regulation framework, while national reimbursement decisions continue to determine patient access, procurement speed, and clinical uptake across member states.

BRICS countries represent long-term adoption potential because of large diabetes populations, expanding middle-class healthcare demand, and growing digital health infrastructure, but pricing, distribution, import dependency, and clinician training are decisive adoption factors. ASEAN markets are heterogeneous, with higher-income and urban centers demonstrating stronger private-sector uptake than lower-income settings where diabetes technology reimbursement is limited. GCC countries benefit from high healthcare spending, diabetes-focused public health strategies, and investment in specialist care, supporting interest in insulin pumps and automated insulin delivery. NATO membership is less directly tied to CSII demand, but overlapping North American and European healthcare, defense-health, and procurement standards reinforce cybersecurity, supply resilience, data protection, and device quality expectations for connected diabetes technologies.

Key Country Insights in CSII Markets

The United States is the most influential CSII country market, supported by advanced pump portfolios, CGM integration, telehealth-enabled endocrinology, established device clearance pathways, and strong patient advocacy. Canada follows with structured provincial reimbursement variation, while Mexico and Brazil show expanding private-market demand alongside public access constraints and uneven specialist availability. The United Kingdom, Germany, France, Italy, and Spain rely on guideline-led diabetes care, health technology assessment, and reimbursement evaluation, though access speed differs by payer, region, and clinical eligibility criteria. Russia faces a more constrained environment due to procurement complexity, reimbursement limitations, and technology supply considerations.

China and India provide substantial long-term adoption opportunities because of their large diabetes populations, but affordability, awareness, reimbursement development, and specialist capacity strongly influence insulin pump uptake. Japan, South Korea, and Australia show stronger readiness for automated insulin delivery because of advanced clinical infrastructure, high digital health maturity, established diabetes care pathways, and reimbursement or subsidy mechanisms for selected diabetes technologies. Across these countries, the strongest CSII adoption conditions occur where CGM access, pump training, endocrinology capacity, patient education, and payer recognition of outcomes such as time-in-range align within routine diabetes care.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize interoperable, patient-centered CSII platforms that integrate pumps, CGMs, dosing algorithms, mobile connectivity, and secure cloud analytics. Competitive advantage will come from reducing training burden, improving infusion set reliability, extending wear time where clinically validated, simplifying onboarding, and demonstrating measurable outcomes such as increased time-in-range, reduced severe hypoglycemia, and lower diabetes management burden.

Manufacturers and healthcare stakeholders should expand real-world evidence programs, localize affordability strategies, and invest in clinician education for pump initiation, data interpretation, and troubleshooting. Partnerships with payers, diabetes clinics, pharmacies, advocacy groups, and digital health providers can accelerate adoption while ensuring cybersecurity, post-market surveillance, software update governance, and equitable access remain central to commercialization. Leaders should also design region-specific pathways that address reimbursement requirements, local clinical guidelines, language needs, supply continuity, and patient support infrastructure.

Research Methodology

This executive assessment applies a triangulated research methodology combining verified secondary sources, regulatory databases, peer-reviewed clinical literature, public health datasets, reimbursement policies, product labeling, medical device clearance records, and diabetes care guidelines. Sources are evaluated for credibility, recency, geographic relevance, methodological transparency, and consistency with established clinical and regulatory evidence.

Insights are strengthened through market mapping across device types, end-user settings, reimbursement environments, regional access conditions, clinical adoption barriers, and technology readiness. Findings are interpreted using evidence-based analysis of clinical utility, regulatory feasibility, adoption barriers, competitive positioning, patient usability, cybersecurity considerations, and long-term demand drivers in CSII and automated insulin delivery. No market sizing, market share, or forecasting assumptions are used in this assessment.

Conclusion

CSII is entering a new phase defined by automation, interoperability, AI-assisted personalization, and outcomes-based access expectations. As diabetes prevalence continues to rise globally, insulin pump therapy is positioned to play a larger role in improving glycemic management, reducing patient burden, and supporting data-driven clinical care across type 1 diabetes and selected insulin-requiring type 2 diabetes populations.

The strongest opportunities will favor organizations that combine clinically validated technology with affordability, cybersecurity, usability, regulatory readiness, and regional access strategies. Stakeholders that can translate innovation into trusted, reimbursable, and scalable diabetes care solutions will be best positioned in the evolving CSII ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Continuous Subcutaneous Insulin Infusion Market, by Product Type

  • 7.1. Insulin Pumps
    • 7.1.1. Tethered Pumps
    • 7.1.2. Patch pumps
  • 7.2. Pump Accessories
    • 7.2.1. Infusion sets
    • 7.2.2. Batteries
    • 7.2.3. Reservoirs
    • 7.2.4. Patches
  • 7.3. CSII Software & Digital Platforms
    • 7.3.1. Remote Monitoring App
    • 7.3.2. Data Management & Analytics Platforms
    • 7.3.3. Automated Insulin Delivery

8. Continuous Subcutaneous Insulin Infusion Market, by Insulin Type

  • 8.1. Rapid Acting Analog
  • 8.2. Regular Insulin
  • 8.3. Short Acting

9. Continuous Subcutaneous Insulin Infusion Market, by Technology Type

  • 9.1. Conventional Insulin Pumps
  • 9.2. Sensor-Augmented Pumps
  • 9.3. Advanced Closed-Loop Systems

10. Continuous Subcutaneous Insulin Infusion Market, by Age Group

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Continuous Subcutaneous Insulin Infusion Market, by End User

  • 11.1. Ambulatory Care
  • 11.2. Homecare
  • 11.3. Hospitals
  • 11.4. Diabetes clinic

12. Continuous Subcutaneous Insulin Infusion Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Continuous Subcutaneous Insulin Infusion Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Continuous Subcutaneous Insulin Infusion Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. B. Braun SE
  • 16.2. Baxter International, Inc.
  • 16.3. Becton, Dickinson and Company
  • 16.4. Bigfoot Biomedical, Inc.
  • 16.5. BPL Medical Technologies Private Limited
  • 16.6. CeQur SA
  • 16.7. F. Hoffmann-La Roche Ltd.
  • 16.8. Forbion
  • 16.9. Fresenius SE & Co. KGaA
  • 16.10. Insulet Corporation
  • 16.11. MannKind Corporation
  • 16.12. Medtronic PLC
  • 16.13. MicroPort Scientific Corporation
  • 16.14. Nipro Corporation
  • 16.15. Pharmasense AG
  • 16.16. Sanofi S.A.
  • 16.17. Shinmyung Mediyes CO., LTD.
  • 16.18. SOOIL Developments Co., Ltd.
  • 16.19. Tandem Diabetes Care, Inc.
  • 16.20. Terumo Group
  • 16.21. Ypsomed AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INSULIN PUMPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INSULIN PUMPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TETHERED PUMPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TETHERED PUMPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TETHERED PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PATCH PUMPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PATCH PUMPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PATCH PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PUMP ACCESSORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PUMP ACCESSORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PUMP ACCESSORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFUSION SETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INFUSION SETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFUSION SETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BATTERIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BATTERIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BATTERIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RESERVOIRS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RESERVOIRS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RESERVOIRS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PATCHES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PATCHES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CSII SOFTWARE & DIGITAL PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CSII SOFTWARE & DIGITAL PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CSII SOFTWARE & DIGITAL PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL REMOTE MONITORING APP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL REMOTE MONITORING APP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL REMOTE MONITORING APP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DATA MANAGEMENT & ANALYTICS PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DATA MANAGEMENT & ANALYTICS PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DATA MANAGEMENT & ANALYTICS PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AUTOMATED INSULIN DELIVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AUTOMATED INSULIN DELIVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AUTOMATED INSULIN DELIVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RAPID ACTING ANALOG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RAPID ACTING ANALOG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RAPID ACTING ANALOG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL REGULAR INSULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL REGULAR INSULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL REGULAR INSULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SHORT ACTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SHORT ACTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SHORT ACTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CONVENTIONAL INSULIN PUMPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CONVENTIONAL INSULIN PUMPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CONVENTIONAL INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SENSOR-AUGMENTED PUMPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SENSOR-AUGMENTED PUMPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SENSOR-AUGMENTED PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ADVANCED CLOSED-LOOP SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ADVANCED CLOSED-LOOP SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ADVANCED CLOSED-LOOP SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AMBULATORY CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AMBULATORY CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AMBULATORY CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HOMECARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HOMECARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HOMECARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIABETES CLINIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DIABETES CLINIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIABETES CLINIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PUMP ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CSII SOFTWARE & DIGITAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PUMP ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CSII SOFTWARE & DIGITAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PUMP ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CSII SOFTWARE & DIGITAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PUMP ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CSII SOFTWARE & DIGITAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PUMP ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CSII SOFTWARE & DIGITAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PUMP ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CSII SOFTWARE & DIGITAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PUMP ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CSII SOFTWARE & DIGITAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 150. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PUMP ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 151. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CSII SOFTWARE & DIGITAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 152. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PUMP ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CSII SOFTWARE & DIGITAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PUMP ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CSII SOFTWARE & DIGITAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 175. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 177. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PUMP ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 178. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CSII SOFTWARE & DIGITAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 179. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 186. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PUMP ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 187. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CSII SOFTWARE & DIGITAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 188. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PUMP ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CSII SOFTWARE & DIGITAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. CANADA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. CANADA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. CANADA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 205. CANADA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PUMP ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 206. CANADA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CSII SOFTWARE & DIGITAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 207. CANADA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. CANADA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. CANADA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. CANADA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. MEXICO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. MEXICO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. MEXICO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 214. MEXICO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PUMP ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 215. MEXICO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CSII SOFTWARE & DIGITAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 216. MEXICO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. MEXICO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. MEXICO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. MEXICO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. BRAZIL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. BRAZIL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. BRAZIL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 223. BRAZIL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PUMP ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 224. BRAZIL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CSII SOFTWARE & DIGITAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 225. BRAZIL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. BRAZIL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. BRAZIL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. BRAZIL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED KINGDOM CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED KINGDOM CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED KINGDOM CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED KINGDOM CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PUMP ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED KINGDOM CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CSII SOFTWARE & DIGITAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED KINGDOM CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED KINGDOM CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED KINGDOM CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED KINGDOM CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. GERMANY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. GERMANY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. GERMANY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 241. GERMANY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PUMP ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 242. GERMANY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CSII SOFTWARE & DIGITAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 243. GERMANY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. GERMANY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. GERMANY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. GERMANY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. FRANCE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. FRANCE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. FRANCE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 250. FRANCE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PUMP ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 251. FRANCE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CSII SOFTWARE & DIGITAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 252. FRANCE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. FRANCE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. FRANCE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. FRANCE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. RUSSIA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. RUSSIA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. RUSSIA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 259. RUSSIA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PUMP ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 260. RUSSIA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CSII SOFTWARE & DIGITAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 261. RUSSIA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. RUSSIA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. RUSSIA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. RUSSIA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. ITALY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. ITALY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. ITALY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 268. ITALY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PUMP ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 269. ITALY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CSII SOFTWARE & DIGITAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 270. ITALY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. ITALY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. ITALY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. ITALY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. SPAIN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. SPAIN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. SPAIN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 277. SPAIN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PUMP ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 278. SPAIN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CSII SOFTWARE & DIGITAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 279. SPAIN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. SPAIN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. SPAIN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 282. SPAIN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PUMP ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CSII SOFTWARE & DIGITAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. INDIA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. INDIA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. INDIA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 295. INDIA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PUMP ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 296. INDIA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CSII SOFTWARE & DIGITAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 297. INDIA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. INDIA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. INDIA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 300. INDIA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. JAPAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. JAPAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. JAPAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 304. JAPAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PUMP ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 305. JAPAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CSII SOFTWARE & DIGITAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 306. JAPAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. JAPAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. JAPAN CONTINUOUS SUBCUT